FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283451352> ?p ?o ?g. }

• W4283451352 endingPage "524" @default.
• W4283451352 startingPage "514" @default.
• W4283451352 abstract "Alpha1-antitrypsin (AAT) deficiency results from carriage of a homozygous SERPINA1 Z mutation (proteinase inhibitor [PI] ZZ). The Z allele produces a mutant AAT protein called Z-AAT, which accumulates in hepatocytes and can lead to progressive liver disease and fibrosis. This open-label, phase 2 trial investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with AAT deficiency.We assigned adults with the PI ZZ genotype and liver fibrosis to receive fazirsiran at a dose of 200 mg (cohorts 1 [4 patients] and 2 [8 patients]) or 100 mg (cohort 1b [4 patients]) subcutaneously on day 1 and week 4 and then every 12 weeks. The primary end point was the change from baseline to week 24 (cohorts 1 and 1b) or week 48 (cohort 2) in liver Z-AAT concentrations, which were measured by means of liquid chromatography-mass spectrometry.All the patients had reduced accumulation of Z-AAT in the liver (median reduction, 83% at week 24 or 48). The nadir in serum was a reduction of approximately 90%, and treatment was also associated with a reduction in histologic globule burden (from a mean score of 7.4 [scores range from 0 to 9, with higher scores indicating a greater globule burden] at baseline to 2.3 at week 24 or 48). All cohorts had reductions in liver enzyme concentrations. Fibrosis regression was observed in 7 of 15 patients and fibrosis progression in 2 of 15 patients after 24 or 48 weeks. There were no adverse events leading to trial or drug discontinuation. Four serious adverse events (viral myocarditis, diverticulitis, dyspnea, and vestibular neuronitis) resolved.In this small trial, fazirsiran was associated with a strong reduction of Z-AAT concentrations in the serum and liver and concurrent improvements in liver enzyme concentrations. (Funded by Arrowhead Pharmaceuticals; AROAAT-2002 ClinicalTrials.gov number, NCT03946449.)." @default.
• W4283451352 created "2022-06-26" @default.
• W4283451352 creator A5001058333 @default.
• W4283451352 creator A5001144757 @default.
• W4283451352 creator A5006242340 @default.
• W4283451352 creator A5023770385 @default.
• W4283451352 creator A5023914331 @default.
• W4283451352 creator A5051528550 @default.
• W4283451352 creator A5052059601 @default.
• W4283451352 creator A5063868149 @default.
• W4283451352 creator A5074767185 @default.
• W4283451352 creator A5082366563 @default.
• W4283451352 creator A5083791996 @default.
• W4283451352 creator A5088819565 @default.
• W4283451352 creator A5089509231 @default.
• W4283451352 date "2022-08-11" @default.
• W4283451352 modified "2023-10-16" @default.
• W4283451352 title "Fazirsiran for Liver Disease Associated with Alpha₁-Antitrypsin Deficiency" @default.
• W4283451352 cites W1484734537 @default.
• W4283451352 cites W1964288182 @default.
• W4283451352 cites W1964572117 @default.
• W4283451352 cites W1977498240 @default.
• W4283451352 cites W2058757351 @default.
• W4283451352 cites W2063835280 @default.
• W4283451352 cites W2080363121 @default.
• W4283451352 cites W2090738619 @default.
• W4283451352 cites W2124879124 @default.
• W4283451352 cites W2142395184 @default.
• W4283451352 cites W2233119733 @default.
• W4283451352 cites W2601839973 @default.
• W4283451352 cites W2623365046 @default.
• W4283451352 cites W2787643951 @default.
• W4283451352 cites W2888207000 @default.
• W4283451352 cites W2914319009 @default.
• W4283451352 cites W2945920646 @default.
• W4283451352 cites W3023605248 @default.
• W4283451352 cites W3154897461 @default.
• W4283451352 cites W4211049690 @default.
• W4283451352 cites W4229038316 @default.
• W4283451352 cites W4248532682 @default.
• W4283451352 cites W4280538144 @default.
• W4283451352 doi "https://doi.org/10.1056/nejmoa2205416" @default.
• W4283451352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35748699" @default.
• W4283451352 hasPublicationYear "2022" @default.
• W4283451352 type Work @default.
• W4283451352 citedByCount "27" @default.
• W4283451352 countsByYear W42834513522022 @default.
• W4283451352 countsByYear W42834513522023 @default.
• W4283451352 crossrefType "journal-article" @default.
• W4283451352 hasAuthorship W4283451352A5001058333 @default.
• W4283451352 hasAuthorship W4283451352A5001144757 @default.
• W4283451352 hasAuthorship W4283451352A5006242340 @default.
• W4283451352 hasAuthorship W4283451352A5023770385 @default.
• W4283451352 hasAuthorship W4283451352A5023914331 @default.
• W4283451352 hasAuthorship W4283451352A5051528550 @default.
• W4283451352 hasAuthorship W4283451352A5052059601 @default.
• W4283451352 hasAuthorship W4283451352A5063868149 @default.
• W4283451352 hasAuthorship W4283451352A5074767185 @default.
• W4283451352 hasAuthorship W4283451352A5082366563 @default.
• W4283451352 hasAuthorship W4283451352A5083791996 @default.
• W4283451352 hasAuthorship W4283451352A5088819565 @default.
• W4283451352 hasAuthorship W4283451352A5089509231 @default.
• W4283451352 hasBestOaLocation W42834513521 @default.
• W4283451352 hasConcept C126322002 @default.
• W4283451352 hasConcept C181199279 @default.
• W4283451352 hasConcept C2777075537 @default.
• W4283451352 hasConcept C2780535462 @default.
• W4283451352 hasConcept C2780559512 @default.
• W4283451352 hasConcept C2781278919 @default.
• W4283451352 hasConcept C55493867 @default.
• W4283451352 hasConcept C71924100 @default.
• W4283451352 hasConcept C72563966 @default.
• W4283451352 hasConcept C86803240 @default.
• W4283451352 hasConcept C90924648 @default.
• W4283451352 hasConceptScore W4283451352C126322002 @default.
• W4283451352 hasConceptScore W4283451352C181199279 @default.
• W4283451352 hasConceptScore W4283451352C2777075537 @default.
• W4283451352 hasConceptScore W4283451352C2780535462 @default.
• W4283451352 hasConceptScore W4283451352C2780559512 @default.
• W4283451352 hasConceptScore W4283451352C2781278919 @default.
• W4283451352 hasConceptScore W4283451352C55493867 @default.
• W4283451352 hasConceptScore W4283451352C71924100 @default.
• W4283451352 hasConceptScore W4283451352C72563966 @default.
• W4283451352 hasConceptScore W4283451352C86803240 @default.
• W4283451352 hasConceptScore W4283451352C90924648 @default.
• W4283451352 hasIssue "6" @default.
• W4283451352 hasLocation W42834513521 @default.
• W4283451352 hasLocation W42834513522 @default.
• W4283451352 hasOpenAccess W4283451352 @default.
• W4283451352 hasPrimaryLocation W42834513521 @default.
• W4283451352 hasRelatedWork W2143427275 @default.
• W4283451352 hasRelatedWork W2315085516 @default.
• W4283451352 hasRelatedWork W2316407790 @default.
• W4283451352 hasRelatedWork W2461352391 @default.
• W4283451352 hasRelatedWork W2487182153 @default.
• W4283451352 hasRelatedWork W2603773853 @default.
• W4283451352 hasRelatedWork W2888207000 @default.
• W4283451352 hasRelatedWork W2904812964 @default.

• next